Advertisement
Australia markets close in 3 hours 17 minutes
  • ALL ORDS

    7,977.30
    -25.20 (-0.31%)
     
  • ASX 200

    7,726.00
    -23.70 (-0.31%)
     
  • AUD/USD

    0.6637
    -0.0000 (-0.00%)
     
  • OIL

    78.20
    -0.42 (-0.53%)
     
  • GOLD

    2,320.90
    +2.90 (+0.13%)
     
  • Bitcoin AUD

    100,695.80
    -1,488.02 (-1.46%)
     
  • CMC Crypto 200

    1,420.36
    +7.40 (+0.52%)
     
  • AUD/EUR

    0.6176
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0777
    +0.0024 (+0.22%)
     
  • NZX 50

    11,860.45
    -12.19 (-0.10%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,163.67
    -51.81 (-0.63%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,265.68
    -365.18 (-1.96%)
     
  • Hang Seng

    17,972.08
    -140.55 (-0.78%)
     
  • NIKKEI 225

    38,709.02
    -11.45 (-0.03%)
     

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

BiomX
BiomX

GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Tuesday, May 21, 2024, at 8:00 a.m. ET, to report first quarter 2024 financial results and provide business and program updates.

To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com